Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

591
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
591
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

530
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
530
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

593
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
593
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

470
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

620
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
620
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

367
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
367

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the Hidden Rules: Enhancing NMD Prediction for Protein-Truncating Variants.

bioRxiv : the preprint server for biology·2026
Same author

Variant Site-Specific Natural History of Titin-Induced Cardiomyopathy: An International Multicenter Registry.

Circulation. Genomic and precision medicine·2026
Same author

The role of cardiac myosin activators in dilated cardiomyopathy pharmacotherapy.

Expert opinion on pharmacotherapy·2026
Same author

Sex and Age Specific Genetic Risk Across the Dilated and Arrhythmogenic Cardiomyopathy Spectrum: Insights From the SHaRe Registry.

Journal of the American College of Cardiology·2026
Same author

External validation of the DSP-risk score for prediction of clinically significant ventricular arrhythmias in primary prevention patients with desmoplakin cardiomyopathy-associated genetic variants.

Heart rhythm·2026
Same author

RBM20 Truncating Variants and Human Cardiomyopathy.

JAMA cardiology·2026

Related Experiment Video

Updated: Feb 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Genetic Infiltrative Cardiomyopathies.

Mary E Sweet1, Luisa Mestroni1, Matthew R G Taylor1

  • 1Adult Medical Genetics Program, Cardiovascular Institute, University of Colorado Anschutz, 12700 East 19th Avenue, Aurora, CO 80045, USA.

Heart Failure Clinics
|March 12, 2018
PubMed
Summary

Inherited infiltrative cardiomyopathies involve abnormal substance deposition in the heart, causing dysfunction. This review details genetic causes, mechanisms, cardiac effects, and treatments for these conditions.

Keywords:
AmyloidosisCardiac oxalosisDanon diseaseFabry diseaseFriedreich ataxiaHemochromatosisMucopolysaccharidosisPRKAG2 syndrome

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

664

Related Experiment Videos

Last Updated: Feb 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

664

Area of Science:

  • Cardiology
  • Genetics
  • Pathology

Background:

  • Infiltrative cardiomyopathies result from abnormal substance accumulation in cardiac tissue.
  • These conditions can be inherited, stemming from specific gene mutations.
  • They present with diverse extracardiac features and overlapping cardiac phenotypes.

Purpose of the Study:

  • To provide a comprehensive overview of inherited infiltrative cardiomyopathies.
  • To describe causative genes, pathological mechanisms, and cardiac manifestations.
  • To outline current and developing therapeutic strategies.

Main Methods:

  • Literature review of inherited infiltrative cardiomyopathies.
  • Analysis of genetic bases and pathogenic pathways.
  • Synthesis of clinical cardiac presentations and treatment options.

Main Results:

  • Detailed descriptions of various inherited infiltrative cardiomyopathies.
  • Identification of key genes and their roles in disease pathogenesis.
  • Summary of the spectrum of cardiac dysfunction and therapeutic interventions.

Conclusions:

  • Understanding the genetic underpinnings is crucial for diagnosing and managing infiltrative cardiomyopathies.
  • Targeted therapies are emerging for specific genetic defects.
  • Further research is needed to improve treatment outcomes.